A COMPARATIVE STUDY OF ALCOHOL CRAVING SCORES BETWEEN PATIENTS RECEIVING NALTREXONE AND ACAMPROSATE FOR ALCOHOL USE DISORDER

Authors: Kanakadurga Goli*, Gunda Sairam

DOI:

DOI: DOI.ORG/10.59551/IJHMP/25832069/2026.7.3/4.114

ABSTRACT:

Background: Craving drives relapse in alcohol use disorder, but head to head evidence on how naltrexone and acamprosate compare on craving is mixed, and Indian data are scarce.

Methods: A prospective, randomized, open label comparative study was conducted at a rural tertiary care hospital in Telangana from October 2024 to September 2025. It enrolled 120 detoxified adults with alcohol use disorder, 60 per arm, to naltrexone 50 mg or acamprosate 1998 mg daily for 12 weeks. Craving was measured with the Penn Alcohol Craving Scale at baseline, 4, 8 and 12 weeks. Analysis used t tests, chi-square tests and odds ratios with 95% confidence intervals.

Results: Groups were comparable at baseline, with craving scores of 19.2 ± 3.4 and 19.5 ± 3.6. At week 12, naltrexone produced a greater reduction, 13.1 ± 5.0 against 9.4 ± 5.6, mean difference 3.7, 95% CI 1.78 to 5.62, p<0.05. Craving response was 75.0% against 51.7%, odds ratio 2.81, 95% CI 1.30 to 6.08. Abstinence was 55.0% against 35.0%, odds ratio 2.27, 95% CI 1.09 to 4.73. Relapse to heavy drinking was 23.3% against 43.3%, odds ratio 0.40, 95% CI 0.18 to 0.87. Nausea was commoner with naltrexone and diarrhoea with acamprosate.

Conclusion: Naltrexone reduced alcohol craving and relapse more than acamprosate over 12 weeks, with an acceptable tolerability profile.

KEYWORDS: Naltrexone, Acamprosate, Alcohol Craving, Alcohol Use Disorder, Penn Alcohol Craving Scale.

Full Text Article (PDF)